Literature DB >> 2292201

Pharmacokinetics of ciprofloxacin in liver cirrhosis.

M Ruhnke1, M Trautmann, K Borner, W Hopfenmüller.   

Abstract

The pharmacokinetics of ciprofloxacin were evaluated in 11 patients (3 patients with impaired renal function) with advanced liver cirrhosis after a single oral dose of 500 mg. Mean serum peaks were 2.80 +/- 1.00 mg/l in 64 +/- 37 min after intake in patients with normal renal function. Elimination was reduced in comparison with healthy volunteers: t1/2 beta 510 +/- 158 min with a total area under the curve of 18.2 +/- 10.3 mg x h/l. Mean recovery of the parent compound from urine was 38 +/- 9% of the dose. In 3 patients with cirrhosis plus poor renal function, elimination was markedly reduced. In patients under 60 years with good renal function, the standard does not require a reduction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292201     DOI: 10.1159/000238793

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli; J F Flaherty; E Wolfe; N Bass; K Somberg
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 2.  Pharmacokinetics of temafloxacin after multiple oral administration.

Authors:  G R Granneman
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

3.  Pharmacokinetics of temafloxacin in patients with liver impairment.

Authors:  G R Granneman; G Mahr; C Locke; P Nickel; W Kirch; W Fabian; M Kinzig; K G Naber; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 4.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.